Director Tiffany Sullivan gets 40,000-share RSU award at Pulmonx (LUNG)

Rhea-AI Filing Summary

Sullivan Tiffany reported acquisition or exercise transactions in this Form 4 filing.

Pulmonx Corp director Tiffany Sullivan received an equity grant in the form of restricted stock units. The Form 4 reports an award of 40,000 shares of common stock at a price of $0.0000 per share, reflecting a compensation-related grant rather than an open-market purchase.

The RSU Grant vests on the earlier of the one-year anniversary of the grant date of June 5, 2026 (or the next business day) or the date of the Annual Meeting of the Stockholders for the year after the grant. Following this grant, Sullivan directly holds 115,199 common shares.

Insights

Equity compensation analyst

Routine director RSU grant increases equity-based compensation without market buying or selling.

Pulmonx Corp granted director Tiffany Sullivan 40,000 restricted stock units payable in common stock at $0.0000 per share. This is classified as a grant/award acquisition, indicating stock-based compensation rather than a cash outlay by the director or an open-market transaction.

The footnote explains these RSUs vest on the earlier of the one-year anniversary of the June 5, 2026 grant date or the next Annual Meeting of the Stockholders. After the award, Sullivan holds 115,199 shares directly, suggesting this is a standard alignment-of-interests move rather than a signal-driven trade.

Insider Trade Summary

Net Buyer: 40,000 shares

Net Buy 1 txn

Insider Sullivan Tiffany

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	40,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 115,199 shares (Direct)

Footnotes (1)

1. F1. Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant of June 5, 2026, or if such date is not a business day, then on the next business day, or (ii) the date of the Annual Meeting of the Stockholders for the year subsequent to the date such RSU Grant is made.

Key Figures

RSU grant size: 40,000 shares Grant price per share: $0.0000 per share Shares after transaction: 115,199 shares +1 more

4 metrics

RSU grant size 40,000 shares Restricted Stock Units granted to director on June 5, 2026

Grant price per share $0.0000 per share Reported transaction price for RSU award

Shares after transaction 115,199 shares Total Pulmonx common shares held by Sullivan following grant

Vesting trigger date June 5, 2026 One-year anniversary used as one vesting condition

Key Terms

Restricted Stock Units, RSU Grant, Annual Meeting of the Stockholders, grant, award, or other acquisition

4 terms

Restricted Stock Units financial

"Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSU Grant financial

"Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock"

Annual Meeting of the Stockholders financial

"or (ii) the date of the Annual Meeting of the Stockholders for the year subsequent"

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/09/2026 - 06:51 PM Accepted by SEC EDGAR 06/09/2026 - 05:54 PM Learn about SEC filing dates

FAQ

What insider transaction did Pulmonx Corp (LUNG) disclose for Tiffany Sullivan?

Pulmonx Corp disclosed that director Tiffany Sullivan received a grant of 40,000 restricted stock units in common stock at $0.0000 per share. This is a compensation award, not an open-market trade, and increases her direct equity stake in the company.

How many Pulmonx (LUNG) shares were included in Tiffany Sullivan’s latest grant?

The filing reports a grant covering 40,000 shares of Pulmonx common stock via restricted stock units. These shares are awarded at no cash cost to Sullivan, reflecting equity compensation designed to align director incentives with shareholder interests over time.

What is the vesting schedule for Tiffany Sullivan’s Pulmonx (LUNG) RSU grant?

The RSU Grant vests on the earlier of the one-year anniversary of the June 5, 2026 grant date, or the date of the Annual Meeting of the Stockholders for the following year. If the anniversary is not a business day, vesting moves to the next business day.

Is Tiffany Sullivan’s Pulmonx (LUNG) RSU grant an open-market stock purchase?

No, the transaction is reported as a grant, award, or other acquisition of 40,000 restricted stock units at $0.0000 per share. This indicates stock-based compensation, not a purchase made on the open market using personal funds.

How many Pulmonx (LUNG) shares does Tiffany Sullivan hold after the RSU grant?

After the reported grant, Tiffany Sullivan directly holds 115,199 shares of Pulmonx common stock. This total reflects the updated position following the 40,000-share restricted stock unit award described in the Form 4 filing.

Does the Pulmonx (LUNG) Form 4 show any stock sales by Tiffany Sullivan?

The Form 4 shows only an acquisition coded as a grant/award of 40,000 restricted stock units. There are no reported sales, dispositions, or derivative exercises in this filing, indicating the transaction solely increased her equity holdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sullivan Tiffany

(Last) (First) (Middle)

C/O PULMONX CORPORATION

700 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pulmonx Corp [ LUNG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		40,000(1)	A	$0	115,199	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant of June 5, 2026, or if such date is not a business day, then on the next business day, or (ii) the date of the Annual Meeting of the Stockholders for the year subsequent to the date such RSU Grant is made.

	/s/ David Aaron Lehman, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)